Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia
TORONTO, March 9, 2021 /PRNewswire/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the Australian Patent Office ("IP Australia") has granted Australian Patent No. AU 2018210690 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038.
Canntab's Legal Counsel on intellectual property, Gavin Bogle of Magyar, Bogle & O'Hara LLP said, "The allowance of Canntab's patent by the Australian Patent Office continues to further provide fundamental intellectual protection for Canntab's innovative tableting technology and even further validates the years of research and development the Company has conducted. The Company now has patent protection in the USA, Canada and Australia providing an international scope to the Company's expanding portfolio of issued patents."
Canntab believes its hard pill formulations are superior to all other medical CBD and THC delivery systems since they are true pharmaceutical grade delivery systems which provide superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing, as opposed to the widely available gel capsule products from other suppliers.
Canntab has eleven pending patent applications internationally and three patents which have now been granted. Canntab has developed both patented and patent pending technologies to deliver standardized medical cannabis extract in a variety of extended-release/ sustained-release pharmaceutical grade delivery systems.